In a significant development today, Justice Endlaw of the Delhi High Court held that ‘export’ of a patented invention for experimental purposes is also covered under Section 107A of the Patents Act, 1970 (India’s Bolar exemption) and thus does not amount to patent infringement. It accordingly allowed Natco to export Bayer’s patented drug ‘Sorafenib Tosylate’ (for which it was granted a compulsory license in 2012) to China for the purpose of conducting development/ clinical studies and trials.

https://akhileship.com/News_and_Publication/wp-content/uploads/2017/03/HD_Patent_War_1600x900-1024x576.pnghttps://akhileship.com/News_and_Publication/wp-content/uploads/2017/03/HD_Patent_War_1600x900-150x150.pngadminaipPatentsIn a significant development today, Justice Endlaw of the Delhi High Court held that ‘export’ of a patented invention for experimental purposes is also covered under Section 107A of the Patents Act, 1970 (India’s Bolar exemption) and thus does not amount to patent infringement. It accordingly allowed Natco to...from the desk of Akhilesh Gupta